摘要
目的探讨恩替卡韦联合糖皮质激素在早期乙型肝炎相关肝衰竭中的应用效果。方法纳入2016年1月～2017年11月90例早期乙型肝炎相关肝衰竭患者以随机数字表法分组。对照组采用恩替卡韦进行治疗,观察组采用恩替卡韦联合糖皮质激素治疗。比较两组早期乙型肝炎相关肝衰竭治疗效果;平均住院时间;干预前后患者血清ALB、TBIL、AST和ALT、凝血酶原时间;不良反应发生率;HBV-DNA转阴率和HBeAg转阴率。结果观察组早期乙型肝炎相关肝衰竭治疗效果高于对照组,差异有统计学意义(P <0.05);观察组平均住院时间短于对照组,差异有统计学意义(P <0.05);干预前两组血清ALB、TBIL、AST和ALT、凝血酶原时间相近,差异无统计学意义(P> 0.05);干预后观察组血清ALB、TBIL、AST和ALT、凝血酶原时间优于对照组,差异有统计学意义(P <0.05)。观察组不良反应少于对照组,差异有统计学意义(P<0.05);观察组HBV-DNA转阴率和HBeAg转阴率与对照组比较,差异无统计学意义(P> 0.05)。结论恩替卡韦联合糖皮质激素在早期乙型肝炎相关肝衰竭中的应用效果确切,可有效改善临床症状,减少并发症,改善肝功能,缩短住院时间,值得推广应用。
Objective To investigate the effect of entecavir combined with glucocorticoids in the early hepatitis B related liver failure. Methods Ninety patients with early hepatitis B related liver failure from January 2016 to November 2017 were included and grouped by digital table. The control group was treated with entecavir. The observation group was treated with entecavir and glucocorticoid. The treatment effect of hepatitis B related liver failure, the average length of hospital stay, serum ALB, TBIL, AST and ALT, prothrombin time, incidence of adverse reactions, HBV-DNA negative rate and HBeAg negative rate before and after intervention were compared between two groups. Results The therapeutic effect of early hepatitis B related liver failure in the observation group was better than that in the control group（P 〈 0.05）; The average length of stay in the observation group was shorter than that in the control group（P 〈 0.05）; The levels of serum ALB, TBIL, AST and ALT and prothrombin time were similar in the two groups before intervention（P 〉 0.05）; The levels of serum ALB, TBIL, AST and ALT and prothrombin time in observation group were better than those in control group after intervention（P 〈 0.05）. Adverse reaction in the observation group was less than that in the control group（P 〈 0.05）. There was no significant difference in HBV-DNA negative rate and HBeAg negative rate between the observation group and the control group（P 〉 0.05）. Conclusion The effect of entecavir combined with glucocorticoids in the early hepatitis B related liver failure is effective, which can effectively improve clinical symptoms, reduce complications, improve liver function and shorten the length of hospital stay, which is worth popularizing and applying.
作者
陈珑斌
CHEN Longbin(Department of Infectious Diseases, the Third Hospital of Xiamen City, Xiamen 361100, China)
出处
《中国医药科学》
2018年第18期31-34,共4页
China Medicine And Pharmacy
